Compare NNBR & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | TLPH |
|---|---|---|
| Founded | 1980 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 37.9M |
| IPO Year | 1996 | 2010 |
| Metric | NNBR | TLPH |
|---|---|---|
| Price | $1.24 | $0.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 212.4K | 204.0K |
| Earning Date | 06-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $770,657,000.00 | $2,151,000.00 |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $0.38 |
| 52 Week High | $2.67 | $1.57 |
| Indicator | NNBR | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 30.95 | 43.10 |
| Support Level | $1.20 | $0.76 |
| Resistance Level | $1.43 | $0.88 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 6.17 | 34.89 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.